, Volume 78, Issue 11, pp 1163–1168 | Cite as

Avatrombopag: First Global Approval

  • Matt ShirleyEmail author
AdisInsight Report


Avatrombopag (Doptelet®) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. A Marketing Authorization Application for use of avatrombopag in this indication was submitted to the EMA in April 2018. Clinical development of avatrombopag in the treatment of other thrombocytopenic disorders, including immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, is ongoing. This article summarizes the milestones in the development of avatrombopag leading to this first approval for the treatment of thrombocytopenia in adult patients with CLD.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol. 2012;19(5):392–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Qureshi K, Patel S, Meillier A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: review of current evidence. Int J Hepatol. 2016;2016:1802932.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–24.CrossRefPubMedGoogle Scholar
  5. 5.
    US FDA. Doptelet® (avatrombopag) tablets: US prescribing information. 2018. Accessed 21 Jun 2018.
  6. 6.
    Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018. Scholar
  7. 7.
    US FDA. FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure [media release]. 2018. Accessed 21 Jun 2018.
  8. 8.
    Dova Pharmaceuticals. Dova Pharmaceuticals announces FDA acceptance of the avatrombopag new drug application (NDA) with Priority Review [media release]. 2017. Accessed 21 Jun 2018.
  9. 9.
    Dova Pharmaceuticals. Dova Pharmaceuticals reports first quarter 2018 operating and financial results [media release]. 2018. Accessed 21 Jun 2018.
  10. 10.
    US FDA. Orphan drug designations and approvals. 2011. Accessed 21 Jun 2018.
  11. 11.
    Dova Pharmaceuticals. Dova Pharmaceuticals provides update on development strategy for avatrombopag in immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT) [media release]. 2018. Accessed 21 Jun 2018.
  12. 12.
    Eisai Co. Ltd. Eisai completes acquisition of MGI Pharma [media release]. 2008. Accessed 21 Jun 2018.
  13. 13.
    Eisai Co. Ltd. Eisai completes acquisition of AkaRx, Inc. and continues development of AKR-501 for thrombocytopenia [media release]. 2010. Accessed 21 Jun 2018.
  14. 14.
    Eisai Co. Ltd. Eisai’s U.S. subsidiary Eisai Inc. enters share purchase agreement concerning AkaRx Inc. in the U.S. [media release]. 2016. Accessed 21 Jun 2018.
  15. 15.
    Dova Pharmaceuticals. Dova Pharmaceuticals signs exclusive distribution agreement with Fosun Pharma for mainland China and Hong Kong [media release]. 2018. Accessed 21 Jun 2018.
  16. 16.
    Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61(6):1253–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Frelinger AL, Koganov ES, Forde EE, et al. Avatrombopag, a novel thrombopoietin receptor agonist, increases platelet counts without increasing platelet activation in patients with thrombocytopenia due to chronic liver disease [abstract]. Blood. 2017;130(Suppl 1):290.Google Scholar
  18. 18.
    Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev. 2018;7(2):188–95.CrossRefPubMedGoogle Scholar
  19. 19.
    Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Jurczak W, Chojnowski K, Mayer J, et al. Avatrombopag, a novel oral thrombopoietin receptor agonist, demonstrates superiority to placebo for the treatment of chronic immune thrombocytopenic purpura in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial [abstract]. Blood. 2017;130(Suppl 1):17.Google Scholar
  22. 22.
    US FDA. Promacta® (eltrombopag) tablets: US prescribing information. 2017. Accessed 21 Jun 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations